Boris K. Lin
About
Boris K. Lin is a scholar working on Molecular Biology, Oncology and Hematology.
According to data from OpenAlex, Boris K. Lin has authored 50 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 21 papers in Oncology and 16 papers in Hematology. Recurrent topics in Boris K. Lin's work include Multiple Myeloma Research and Treatments (15 papers), Lymphoma Diagnosis and Treatment (10 papers) and Lung Cancer Treatments and Mutations (8 papers). Boris K. Lin is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Lymphoma Diagnosis and Treatment (10 papers) and Lung Cancer Treatments and Mutations (8 papers). Boris K. Lin collaborates with scholars based in United States, Germany and United Kingdom. Boris K. Lin's co-authors include Kenneth C. Anderson, Teru Hideshima, Dharminder Chauhan, Yu‐Tzu Tai, Faith E. Davies, Klaus Podar, Paul G. Richardson, Noopur Raje, George W. Muller and David Stirling and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
In The Last Decade
Boris K. Lin
48 papers receiving 4.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Boris K. Lin United States | 26 | 2.8k | 2.4k | 1.6k | 543 | 505 | 50 | 4.4k | ||
| Enrique M. Ocio Spain | 41 | 2.7k 1.0× | 2.6k 1.1× | 1.9k 1.2× | 1.4k 2.6× | 1.1k 2.3× | 206 | 5.2k | ||
| Güllü Görgün United States | 31 | 1.7k 0.6× | 1.5k 0.6× | 1.4k 0.9× | 894 1.6× | 672 1.3× | 74 | 3.8k | ||
| José A. Martínez-Climent Spain | 39 | 1.9k 0.7× | 952 0.4× | 1.3k 0.8× | 865 1.6× | 1.0k 2.1× | 135 | 4.5k | ||
| Ruben D. Carrasco United States | 26 | 2.4k 0.9× | 1.2k 0.5× | 1.3k 0.8× | 291 0.5× | 313 0.6× | 64 | 3.8k | ||
| Andrzej Jakubowiak United States | 43 | 4.2k 1.5× | 4.1k 1.7× | 3.1k 2.0× | 454 0.8× | 293 0.6× | 262 | 6.3k | ||
| Ali G. Turhan France | 37 | 1.5k 0.5× | 2.0k 0.9× | 1.0k 0.7× | 1.4k 2.6× | 332 0.7× | 184 | 4.0k | ||
| Sonia Vallet United States | 31 | 1.8k 0.6× | 1.4k 0.6× | 1.5k 0.9× | 322 0.6× | 310 0.6× | 104 | 3.3k | ||
| Claudia Scholl Germany | 32 | 2.7k 1.0× | 2.0k 0.8× | 688 0.4× | 676 1.2× | 260 0.5× | 72 | 4.2k | ||
| J. Blake Bartlett United Kingdom | 20 | 1.6k 0.6× | 1.7k 0.7× | 1.2k 0.8× | 560 1.0× | 522 1.0× | 46 | 3.0k | ||
| Eline Menu Belgium | 41 | 2.9k 1.1× | 1.8k 0.8× | 1.4k 0.9× | 283 0.5× | 217 0.4× | 131 | 4.3k |
Countries citing papers authored by Boris K. Lin
Since
Specialization
Citations
This map shows the geographic impact of Boris K. Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boris K. Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boris K. Lin more than expected).
Fields of papers citing papers by Boris K. Lin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Boris K. Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boris K. Lin. The network helps show where Boris K. Lin may publish in the future.
Co-authorship network of co-authors of Boris K. Lin
This figure shows the co-authorship network connecting the top 25 collaborators of Boris K. Lin. A scholar is included among the top collaborators of Boris K. Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boris K. Lin. Boris K. Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pérol, M., Kōichi Goto, Benjamin Solomon, et al.. (2024). Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.. Journal of Clinical Oncology. 42(16_suppl). 8547–8547.
2.
Brose, Marcia S., Bruce Robinson, Lori J. Wirth, et al.. (2024). Comparative patient-reported tolerability (PRT): A multiplicity-controlled analysis of LIBRETTO-531, a randomized controlled trial (RCT) in medullary thyroid cancer (MTC).. Journal of Clinical Oncology. 42(16_suppl). 11111–11111.
3.
Pérol, M., Benjamin Solomon, Kōichi Goto, et al.. (2024). CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer. Journal of Clinical Oncology. 42(21). 2500–2505.
4.
Sweeney, Christopher J., Ivor Percent, Sunil Babu, et al.. (2022). Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 28(11). 2237–2247.
5.
Solomon, Benjamin, Herbert H. Loong, Yvonne Summers, et al.. (2022). Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. ESMO Open. 7(2). 100398–100398.
6.
Loong, Herbert H., Kōichi Goto, Yasir Y. Elamin, et al.. (2020). 1413TiP LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S893–S893.
7.
Solomon, Benjamin, Alexander Drilon, Keunchil Park, et al.. (2020). Phase III Study of Selpercatinib Versus Chemotherapy ± pembrolizumab in Untreated RET Positive Non-Small-Cell Lung Cancer. Future Oncology. 17(7). 763–773.
8.
Smith, Rosamund C., Martin S. Cramer, Pamela J. Mitchell, et al.. (2015). Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting. Molecular Cancer Therapeutics. 14(7). 1661–1670.
9.
Smith, Rosamund C. & Boris K. Lin. (2013). Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Current Opinion in Supportive and Palliative Care. 7(4). 352–360.
10.
Forsyth, Cecily, David Gómez‐Almaguer, Paul Eliadis, et al.. (2013). A Multicenter, Open-Label, Noncomparative Screening Study of Enzastaurin in Adult Patients With Non-Hodgkin Lymphomas. Clinical Lymphoma Myeloma & Leukemia. 13(4). 398–403.
11.
Schwartzberg, Lee S., Róbert Hermann, Ian W. Flinn, et al.. (2012). Phase II Study of Enzastaurin in Patients with Follicular Lymphoma: Updated Final Clinical Results and Immunohistochemical Correlations. Blood. 120(21). 777–777.
12.
Querfeld, Christiane, Timothy M. Kuzel, Youn H. Kim, et al.. (2011). Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leukemia & lymphoma. 52(8). 1474–1480.
13.
Li, Shuyu, Michael Lahn, Leslie H. Brail, et al.. (2007). Retrospective analysis of protein kinase C-beta (PKC-β) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas. Biology Direct. 2(1). 8–8.
14.
Raab, Marc S., Jing Zhang, Douglas W. McMillin, et al.. (2006). Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).. Blood. 108(11). 3466–3466.
15.
Lentzsch, Suzanne, Richard LeBlanc, Klaus Podar, et al.. (2003). Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 17(1). 41–44.
16.
Weisberg, Ellen, YT Tai, Boris K. Lin, et al.. (2002). LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo.. Blood. 100(11).
17.
Podar, Klaus, Yu‐Tzu Tai, Boris K. Lin, et al.. (2002). Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation. Journal of Biological Chemistry. 277(10). 7875–7881.
18.
Tai, Yu‐Tzu, Klaus Podar, Stine‐Kathrein Kraeft, et al.. (2002). Translocation of Ku86/Ku70 to the multiple myeloma cell membrane. Experimental Hematology. 30(3). 212–220.
19.
Shima, Yoshihito, Teru Hideshima, Klaus Podar, et al.. (2001). Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 15(12). 1950–1961.
20.
Xu, Gangfeng, Boris K. Lin, Kazuma Tanaka, et al.. (1990). The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 63(4). 835–841.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Enrique M. Ocio Breakdown of academic impact, for papers by Güllü Görgün Breakdown of academic impact, for papers by José A. Martínez-Climent Breakdown of academic impact, for papers by Ruben D. Carrasco Breakdown of academic impact, for papers by Andrzej Jakubowiak Breakdown of academic impact, for papers by Ali G. Turhan Breakdown of academic impact, for papers by Sonia Vallet Breakdown of academic impact, for papers by Claudia Scholl Breakdown of academic impact, for papers by J. Blake Bartlett Breakdown of academic impact, for papers by Eline Menu